Citi raised the firm’s price target on Acadia Pharmaceuticals (ACAD) to $36 from $33 and keeps a Buy rating on the shares. The firm sees opportunities in SMID-cap biotech heading into 2026 for commercial or near-commercial stage companies. As part of its 2026 outlook, Citi upgraded both Arvinas and Krystal Biotech while adding an “upside 90-day catalyst watch” on Olema Oncology.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
- Acadia Pharmaceuticals price target raised to $34 from $29 at Needham
- Acadia Pharmaceuticals price target raised to $37 from $32 at H.C. Wainwright
- Acadia Pharmaceuticals announces FDA approval of Daybue Stix for oral solution
- Acadia Pharmaceuticals price target raised to $25 from $24 at Stifel
- Acadia Pharmaceuticals price target raised to $29 from $24 at Mizuho